In this May 2016 photo provided by Kite Pharma, cell therapy specialists at the company's manufacturing facility in El Segundo, Calif., prepare blood cells from a patient to be engineered in the lab to fight cancer. The experimental gene therapy, called CAR-T cell, turns a patient's own blood cells into specialized cancer killers and worked in the study, with more than one third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday, Feb. 28, 2017. (Kite Pharma via AP)
An experimental gene therapy that turns a patient's own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.
In all, 82 percent of patients had their cancer shrink at least by half at some point in the study.
Its sponsor, California-based Kite Pharma, is racing Novartis AG to become the first to win approval of the treatment, called CAR-T cell therapy, in the U.S. It could become the nation's first approved gene therapy.
A hopeful sign: the number in complete remission at six months 36 percent is barely changed from partial results released after three months, suggesting this one-time treatment might give lasting benefits for those who do respond well.
"This seems extraordinary ... extremely encouraging," said one independent expert, Dr. Roy Herbst, cancer medicines chief at the Yale Cancer Center.
The worry has been how long Kite's treatment would last and its side effects, which he said seem manageable in the study. Follow-up beyond six months is still needed to see if the benefit wanes, Herbst said, but added, "this certainly is something I would want to have available."
The therapy is not without risk. Three of the 101 patients in the study died of causes unrelated to worsening of their cancer, and two of those deaths were deemed due to the treatment.
It was developed at the government's National Cancer Institute and then licensed to Kite. The Leukemia and Lymphoma Society helped sponsor the study.
Results were released by the company and have not been published or reviewed by other experts. Full results will be presented at the American Association for Cancer Research conference in April.
The company plans to seek approval from the U.S. Food and Drug Administration by the end of March and in Europe later this year.
The treatment involves filtering a patient's blood to remove key immune system soldiers called T-cells, altering them in the lab to contain a gene that targets cancer, and giving them back intravenously. Doctors call it a "living drug" permanently altered cells that multiply in the body into an army to fight the disease.
Patients in the study had one of three types of non-Hodgkin lymphoma, a blood cancer, and had failed all other treatments. Median survival for such patients has been about six months.
Kite study patients seem to be living longer, but median survival isn't yet known. With nearly nine months of follow-up, more than half are still alive.
Six months after treatment, 41 percent still had a partial response (cancer shrunk at least in half) and 36 percent were in complete remission (no sign of disease).
"The numbers are fantastic," said Dr. Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study and has been a paid adviser to Kite. "These are heavily treated patients who have no other options."
One of his patients, 43-year-old Dimas Padilla of Orlando, was driving when he got a call saying his cancer was worsening, chemotherapy was no longer working, and there was no match to enable a second try at a stem cell transplant.
"I actually needed to park ... I was thinking how am I going to tell this to my mother, my wife, my children," he said. But after CAR-T therapy last August, he saw his tumors "shrink like ice cubes" and is now in complete remission.
"They were able to save my life," Padilla said.
Of the study participants, 13 percent developed a dangerous condition where the immune system overreacts in fighting the cancer, but that rate is lower than in some other tests of CAR-T therapy. The rate fell during the study as doctors got better at detecting and treating it sooner.
Roughly a third of patients developed anemia or other blood-count-related problems, which Locke said were easily treated. And 28 percent had neurological problems such as sleepiness, confusion, tremor or difficulty speaking, but these typically lasted just a few days, Locke said.
"It's a safe treatment, certainly a lot safer than having progressive lymphoma," and comparable to combination chemotherapy in terms of side effects, said the cancer institute's Dr. Steven Rosenberg, who had no role in Kite's study. The first lymphoma patient Rosenberg treated this way, a Florida man, is still in remission seven years later.
There were no cases of swelling and fluid in the brain in this or any other study testing Kite's treatment, company officials said. That contrasts with Juno Therapeutics, which has had a CAR-T study put on hold twice after five patient deaths due to this problem.
Company officials would not say what the treatment might cost, but other types of immune system therapies have been very expensive. It's also being tested for some other types of blood cancer.
___
Online:
Lymphoma info: http://seer.cancer.gov/statfacts/html/nhl.html
CAR-T therapy: http://www.cancer.gov/about-cancer/treatment/research/car-t-cells
Gene therapy: http://ghr.nlm.nih.gov/primer/therapy/availability
___
Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP .
Read the rest here:
New gene therapy for cancer shows promise in major test - Colorado Springs Gazette
- Glowing embryonic gecko hand and otherworldly slime mold amaze in winning microscope photos - Livescience.com - October 13th, 2022
- Sierra Space, UC San Diego Partner to Develop the First Stem Cell Research Institute in Space - Business Wire - October 4th, 2022
- Second-Line BCL Treatment Landscape Shifts From ASCT to CAR T-Cell Therapy - Targeted Oncology - October 4th, 2022
- CellResearch Corporation reports positive results of DFU trial - Labiotech.eu - September 25th, 2022
- University of Colorado's ocular stem cell and regenerative research program recognized - Ophthalmology Times - September 8th, 2022
- RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies - GlobeNewswire - August 22nd, 2022
- Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma - OncLive - August 22nd, 2022
- Stem Cell Therapy: Update and Clinical Research 2022 - August 14th, 2022
- The engineer who teaches our bodies to heal themselves - EL PAS USA - July 19th, 2022
- Control in Healthcare: History and Reclamation of Bodily Autonomy - Non Profit News - Nonprofit Quarterly - July 19th, 2022
- This Simple Fish May Have Been One of the First Vertebrates - The Scientist - July 11th, 2022
- How Tumor Cells Use Mitochondria to Keep Growing - July 3rd, 2022
- Nearly 75 Percent Of Veterinarians Concerned That Frequent Injections Could Cause Joint Damage - Horse Racing News - Paulick Report - July 3rd, 2022
- OEDIT Announces Recipients of Collaborative Infrastructure Grant - Colorado Office of Economic Development and International Trade - June 22nd, 2022
- Politics Briefing: Conservative leadership race is intense, Bergen says, but she expects party unity once it's over - The Globe and Mail - June 13th, 2022
- Maine health care workers to appeal order to disclose their names in vaccine mandate lawsuit - Press Herald - June 4th, 2022
- America's return to the 19th century - York Dispatch - June 4th, 2022
- Top 10 Most Popular Stem Cell Treatments of 2022 - April 19th, 2022
- Will Smith's Slap at the Oscars Awakens the World to Alopecia Areata - University of Colorado Anschutz Medical Campus - April 19th, 2022
- Northern Colorado Doctor Researching New Treatment Options ... - December 24th, 2021
- Christmas Wish: 4-year-old just wants life-saving treatment for her twin brother - FOX 31 Denver - December 24th, 2021
- Breakthrough infections might not be a big transmission risk. Heres the evidence. - WBEZ - October 16th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Stem Cell Therapy Market Size, Top Key Players, Applications, Business Statistics, Trends and Forecast 2021-2027 The Bisouv Network - The Bisouv... - February 7th, 2021
- More on deadly blizzards | TheFencePost.com - Fence Post - February 7th, 2021
- 'A heart of gold': Rick Schwartz remembered for his commitment to family, community - CTV News - November 13th, 2020
- Alex Trebek died of pancreatic cancer think twice before saying he lost his battle with the disease - MarketWatch - November 13th, 2020
- Culprit Mutations, Risky (Neandertal) Variants, Genomic Analysis App: COVID-19 Updates - Bio-IT World - October 7th, 2020
- Stem Cell Therapy Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - thedailychronicle.in - September 30th, 2020
- Cancer Stem Cells Market is Thriving Worldwide 2020-2027 | Top Companies Merck KGaA, ONCOMED PHARMACEUTICALS INC, Bionomics, MacroGenics, Inc.,... - September 9th, 2020
- 27 De-Stressing Vegan Products to Help You Get Through The Rest of 2020 - VegNews - September 9th, 2020
- THE BONDS OF FRIENDSHIP: OXFORD AND SUNWAY - The Star Online - September 9th, 2020
- Colorados juvenile prisons have avoided COVID-19 outbreaks, but advocates worry about the future - The Denver Post - May 30th, 2020
- Future Leader Winner Using Technology To Solve The Problems He Sees - CBS Denver - May 30th, 2020
- SONDERMANN | Is it time to send a scientist to the Senate? - coloradopolitics.com - April 18th, 2020
- 5 Things to Know About Hemp-CBD In Pet Products - The Fresh Toast - April 18th, 2020
- Alone, together: Isolation in the name of health is familiar - Coloradoan - March 24th, 2020
- Stem Cell Therapy Colorado - thriveMD Denver & Vail, CO - March 20th, 2020
- Little Tissue, Big Mission: Beating Heart Tissues to Ride Aboard The ISS - Newswise - March 9th, 2020
- Denver Regenerative Medicine & Stem Cell Therapy - March 1st, 2020
- 5 most popular innovation stories in Houston this week - InnovationMap - January 5th, 2020
- Chiropractor Denver Announces Hormone Replacement Therapy Colorado Springs to Transform Life of Aging People - Press Release - Digital Journal - November 24th, 2019
- Cord Blood Banking Services Market size with global investment, top companies analysis, new business developments and forecast 2025 - Montana Ledger - November 16th, 2019
- Stem Cell Therapy - Boulder, Colorado | Boulder Biologics |Jason Glowney, MD | Stem Cells - Denver, Colorado | PRP | Regenerative Medicine | EPAT |... - May 20th, 2019
- Stem Cells and Hearing Loss - Sound Relief Hearing Center - May 1st, 2019
- Stem Cell Therapy - Boulder, Colorado | Boulder Biologics ... - April 20th, 2019
- Stem Cell Therapy for Joint Pain and Soft Tissue, Colorado - April 12th, 2019
- Stem Cells from Fat vs. Bone Marrow Best Sources for ... - April 7th, 2019
- CROM Stem Cell Therapy- Denver, Colorado - March 27th, 2019
- Gene expression in stem cells | Data Nuggets - March 7th, 2019
- Denver Stem Cell | Area's Leading Stem Cell Doctors - February 22nd, 2019
- Stem Cell Therapy - Colorado Springs Orthopaedic Group - January 16th, 2019
- Using Stem Cells to Treat Sepsis - Stem Cell Centers, Colorado - November 28th, 2018
- Stem Cell Fraud | Colorado Stem Cell Therapy - November 23rd, 2018
- Colorado Stem Cell Therapy | Home - October 1st, 2018
- FAQ | Colorado Stem Cell Therapy - October 1st, 2018
- Stem Cell Therapy | Spine & Joint Solutions - Colorado Springs - July 29th, 2018
- In Depth About Regenerative Therapy | Regen Colorado - July 25th, 2018
- Pepsi: Aborted Baby Cells in Drink Research | Colorado ... - July 15th, 2018
- Stem Cell Therapy in Colorado | Aspen Integrative Medicine - June 23rd, 2018
- Stem Cell Therapy Denver Colorado - Colorado Rehabilitation - June 18th, 2018
- Stem Cell PRP Therapy | Colorado Stem Cell Therapy - June 18th, 2018
- Stem Cell Therapy - Colorado Springs Orthopedics - October 14th, 2017
- Top Stem Cell Therapy Clinic in Vail & Denver, Colorado ... - September 25th, 2017
- 'Little Frankenstein,' conceived so Minnesota doctors could save sister, is now a happy teen - Minneapolis Star Tribune - June 25th, 2017
- What happens when scientists leave their labs to experiment with politics? - Los Angeles Times - June 21st, 2017
- Regenexx: injections soon will replace orthopedic surgery - Broomfield Enterprise - June 21st, 2017
- How a simple cheek swab can save a life - FOX31 Denver - June 4th, 2017
- Ground broken on new $US65 million facility at Colorado State University - Horsetalk - June 4th, 2017
- SpaceX to launch CU-built heart, bone health experiments to space station - CU Boulder Today - June 4th, 2017
- Translational Medicine Institute launched at Colorado State University - Source - June 4th, 2017
- Giraffe 'sneakers' in use at the Cheyenne Mountain Zoo! - KKTV 11 News - May 24th, 2017
- For the first time ever, researchers produced lab-grown blood stem cells - Colorado Springs Gazette - May 24th, 2017
- Chattanooga Student Surprised to be a Gift of Life Donor - WDEF News 12 - May 24th, 2017
- Is Autologous Heamatopoietic Stem Cell Transplantation Still Viable for MS? - LWW Journals - May 19th, 2017
- Stem Cell Transplants May Work for MS, Study Says - LWW Journals (blog) - April 20th, 2017
- 'Priming' protein boosts stem cell response to injury, promotes healing - FierceBiotech - April 20th, 2017
- Overcoming Opioids: The quest for less addictive drugs - Colorado Springs Gazette - April 20th, 2017
- Climbing mountains for cancer research - The Wilton Bulletin - April 20th, 2017
- Australian of the Year Alan Mackay-Sim on the advantage of being 'an interested scientist' - The Sydney Morning Herald - April 9th, 2017